TEM

Tempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold.

Tempus AI (TEM) shares gained 17.9% over the past month, outperforming peers like Claritev and iRhythm, driven by strong demand for healthcare AI. The company reported 28% revenue growth in its Data and Applications segment to $93.2M in Q2, with Insights revenues up 36%.

However, TEM trades at a premium valuation of 6.59X sales versus the industry average of 4.70X, and its growth depends heavily on regulatory approvals and reimbursement decisions. Analysts recommend current holders maintain positions while prospective investors wait for a more favorable entry point.

Natera announced a strategic collaboration with TransCode Therapeutics to use its Signatera MRD test for identifying eligible patients in a Phase 2a trial evaluating TTX-MC138, an investigational therapy targeting miR-10b in colorectal cancer patients. The partnership aims to accelerate patient enrollment by detecting residual cancer in patients with no detectable disease on imaging, addressing an unmet medical need in early cancer recurrence intervention.

Tempus AI demonstrated improving operating leverage in Q2 2026 with 22% revenue growth to $382.5M and adjusted EBITDA reaching $8M (a $13.6M improvement). The company completed a $460M convertible notes offering expected to reduce annual interest expenses by over $30M. Tempus raised its 2026 revenue guidance to $1.595-$1.605B while maintaining adjusted EBITDA guidance of $65M, supporting its goal of achieving positive free cash flow by year-end 2026.

The global AI in clinical trials market is projected to expand from USD 2.09 billion in 2026 to USD 18.62 billion by 2040, growing at a 17.0% CAGR. AI applications including patient recruitment, predictive analytics, digital twins, and automation are addressing key challenges in drug development timelines and trial efficiency.

Oncology represents the largest therapeutic area, while Asia-Pacific shows significant growth potential. Key players include IQVIA, Medidata, Dassault Systemes, and emerging AI companies like Deep 6 AI and AiCure.